Navigation Links
Killing brain tumors from within: A 'Trojan horse' approach

A new method for targeting malignant brain tumors through inducing the cancerous cells to "commit suicide" has been developed by a team of researchers headed by a Hebrew University of Jerusalem professor of biochemistry.

Alexander Levitzki, who is the Wolfson Family Professor of Biochemistry, his research associate, Dr. Alexei Shir, and his colleagues from the Ludwig-Maximilians University of Munich, Germany, have pioneered a technique in which a molecule containing long, double-stranded RNA is attached to epidermal growth factor (EGF) and delivered selectively to cells with an abnormally high number of epidermal growth factor receptors (EGFR).

This proliferation of EGFR is typical of certain types of cancer cells, including glioblastoma multiforme (GBM), the most lethal form of brain cancer.

The nucleic acid-EFG molecule acts as a "guided missile," explained Prof. Levitzki, which, when injected into the blood stream, is avidly gobbled up by the multiple EGF receptors on the cancer cells, without harming normal cells. Once embedded in the tumor cells, it destroys them from within ?a true "Trojan horse," said Prof. Levitzki. Normal cells, which possess 20 to100 less receptors for EGF, are spared, since the amount of double-stranded RNA gobbled up is insufficient to induce them to die.

The lethal RNA approach has been applied to mice in which human brain tumors were grown. The tests proved 100% effective in eliminating the tumorous growths.

An article on the work of Prof. Levitzki, along with his associate Dr. Shir and Professors Manfred Orgris and Ernst Wagner of Ludwig-Maximilians University in Munich, was published in a recent article in the journal PLOS Medicine.

Further testing is planned in a clinical setting. In the meantime, a small start-up company, Algen Biopharmaceuticals Ltd., has been established through the Hebrew University's Yissum Technology Transfer Company to promote commercial devel opment of the new drug. Prof. Levitzki believes that the project has great potential, especially in view of the fact that over-expression of EGF receptors is involved in over 25 % of all types of cancers. The strategy developed to combat GBM can also be applied to other types of receptors found on cancerous cells, he added.

Last year, Prof. Levitzki was named as a winner of the prestigious Wolf Prize in Medicine for his research on cancer development and treatment. His previous work has already led to successful therapy in treating leukemia and some lung cancer patients.
'"/>

Source:The Hebrew University of Jerusalem


Related biology news :

1. Duke Experiments Boost Radiations Cancer-Killing Effects
2. Killing the messenger RNA -- But which one?
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
5. Mouse brain tumors mimic those in human genetic disorder
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. First atlas of key brain genes could speed research on cancer, neurological diseases
8. NYU study reveals how brains immune system fights viral encephalitis
9. Stem cells from brain transformed to produce insulin at Stanford
10. Birds brains reveal source of songs
11. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile market ... prices have dropped dramatically. The quarterly average price of ... to $276 in Q4 2016.  There are now 120 ... of $116, up from just 28 a year ago ... According to Maxine Most , Acuity Market Intelligence ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
Breaking Biology News(10 mins):
(Date:2/15/2017)... Feb. 15, 2017  NASA provider SpaceX is scheduled ... the  International Space Station  no earlier than 10:01 a.m. ... will begin at 8:30 a.m. on NASA Television and ... spacecraft will lift off on the company,s Falcon ... Kennedy Space Center in ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ ... ), a biotechnology company focused on developing aerosolized ... that it has completed a $10.5 million private ... expects that it has sufficient capital to fund ... 2b clinical trial data release in mid-2017. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Morris ... sixth annual open house and technology show, Morris Madness, March 14-15, 2017 in ... demos from Okuma, Tsugami and Hardinge Group in addition to displays of tooling, ...
(Date:2/15/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 15, 2017 ... on discovering and developing drugs that promote the repair ... million Series A financing led by The Column Group, ... San Francisco . The funds will be used ... unlocking the therapeutic potential of Wnt signaling, which plays ...
Breaking Biology Technology: